[Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy]

Internist (Berl). 2005 Aug;46(8):923-4, 926. doi: 10.1007/s00108-005-1466-x.

[Article in German]

Authors

S Nitschmann¹, M Girndt, H Köhler

Affiliation

¹ Fridinger Strasse 16a, 70619, Stuttgart, Germany. nitschmann@gmx.de

PMID: 15990988
DOI: 10.1007/s00108-005-1466-x

No abstract available

Publication types

Comparative Study

MeSH terms

Adult
Aged
Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Benzimidazoles / adverse effects
Benzimidazoles / therapeutic use*
Benzoates / adverse effects
Benzoates / therapeutic use*
Blood Pressure / drug effects
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / drug therapy*
Diabetic Nephropathies / physiopathology
Double-Blind Method
Enalapril / adverse effects
Enalapril / therapeutic use*
Female
Glomerular Filtration Rate / drug effects
Humans
Male
Middle Aged
Prospective Studies

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Benzimidazoles
Benzoates
Enalapril